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Mechanisms leading to osteoporosis are incompletely understood. Genetic disorders with skeletal 
fragility provide insight into metabolic pathways contributing to bone strength. We evaluated 
6 families with rare skeletal phenotypes and osteoporosis by next-generation sequencing. In all 
the families, we identified a heterozygous variant in SGMS2, a gene prominently expressed in 
cortical bone and encoding the plasma membrane–resident sphingomyelin synthase SMS2. Four 
unrelated families shared the same nonsense variant, c.148C>T (p.Arg50*), whereas the other 
families had a missense variant, c.185T>G (p.Ile62Ser) or c.191T>G (p.Met64Arg). Subjects with 
p.Arg50* presented with childhood-onset osteoporosis with or without cranial sclerosis. Patients 
with p.Ile62Ser or p.Met64Arg had a more severe presentation, with neonatal fractures, severe 
short stature, and spondylometaphyseal dysplasia. Several subjects had experienced peripheral 
facial nerve palsy or other neurological manifestations. Bone biopsies showed markedly altered 
bone material characteristics, including defective bone mineralization. Osteoclast formation 
and function in vitro was normal. While the p.Arg50* mutation yielded a catalytically inactive 
enzyme, p.Ile62Ser and p.Met64Arg each enhanced the rate of de novo sphingomyelin production 
by blocking export of a functional enzyme from the endoplasmic reticulum. SGMS2 pathogenic 
variants underlie a spectrum of skeletal conditions, ranging from isolated osteoporosis to 
complex skeletal dysplasia, suggesting a critical role for plasma membrane–bound sphingomyelin 
metabolism in skeletal homeostasis.
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Introduction
Osteoporosis is a major clinical and public health concern with significant morbidity, disability, and mor-
tality (1) The underlying causes remain incompletely understood. Rare inherited skeletal disorders have 
often shed light on the genetic and molecular mechanisms governing bone health (2). Several such rare 
disorders are associated with early-onset osteoporosis, with or without additional clinical traits. One 
example is osteoporosis with calvarial doughnut lesions (CDLs) (Online Mendelian Inheritance in Man 
[OMIM] #126550). This autosomal dominant skeletal disorder is characterized by low-bone mineral den-
sity, increased spinal and peripheral fractures, and sclerotic, doughnut-shaped lesions in the cranial bones. 
In the current nosology of  skeletal disorders (3), CDL is included with osteogenesis imperfecta (OI) in the 
group of  bone fragility disorders. The genetic cause of  CDL has remained unknown.
Herein, we describe 6 families with a total of  13 subjects affected by early-onset osteoporosis of  vary-
ing severity and a spectrum of  other features, ranging from mild cranial sclerotic lesions characteristic of  
CDL to spondylometaphyseal dysplasia with marked cranial sclerosis. In all affected subjects, we iden-
tified potentially novel heterozygous pathogenic variants in the sphingomyelin synthase 2 gene (SGMS2) 
(NM_001136257, uniprot: Q8NHU3). We performed functional studies to address the pathogenic role of  
these variants. Our findings underscore the importance of  intact plasma membrane–bound sphingomyelin 
metabolism for normal bone mineralization and bone strength.
Results
Patients
Through international collaboration we recruited 6 families (Figure 1A) to the study. The recruitment 
occurred by two means: (a) by asking clinicians about phenotypically matching patients with the combina-
tion of  osteoporosis or fractures and sclerotic cranial lesions, similar to that described in CDL, and, (b) after 
identification of  the gene defect, by genetic and phenotypic match through GeneMatcher (4). The clinical 
data are summarized in Tables 1 and 2 and presented here separately for each family.
Family 1. This Finnish 3-generation family with 3 affected individuals has been previously described (5). 
The index (F1-1) is presently a 23-year-old female with a history of  spinal and peripheral fractures since child-
hood, low-bone mineral density, sclerotic calvarial lesions, recurrent idiopathic peripheral facial nerve palsies 
(Bell’s palsy), and congenital bilateral glaucoma. Her 59-year-old father (F1-2) has a similar skeletal phenotype 
and transient facial, trochlear, and oculomotor nerve palsies with slow recovery; their cause remained unclear 
despite thorough neurological evaluations. The father’s mother (F1-3), who died at age 85 years, had severe 
osteoporosis with sclerotic calvarial lesions, diagnosis of  Alzheimer’s disease, transient peripheral facial nerve 
palsies and episodes of  abducens and oculomotor nerve palsies, and chronic congestive glaucoma.
Family 2. The index (F2-1) is a 27-year-old Finnish male with severe childhood-onset primary osteopo-
rosis and a history of  9 low-energy peripheral fractures, multiple vertebral fractures, and a sclerotic cranial 
lesion. He has had no nerve palsies or ophthalmological concerns.
Family 3. The index subject (F3-1) is an 8-year-old White girl from the US with severe early-onset oste-
oporosis, vertebral fractures involving nearly all vertebrae, mild thoracic syringomyelia, mild short stature, 
and no sclerotic cranial lesions. Her older sister (F3-2) has a similar clinical history but also sclerotic cra-
nial lesions. Her younger brother (F3-3) has, at 4 years of  age, low-bone mineral density but no history of  
fractures and no calvarial lesions. Their mother (F3-4), age 38 years, has severe osteoporosis with multiple 
vertebral and peripheral fractures. The mother’s mother (F3-5) has a history of  osteoporosis with multiple 
fractures, cranial sclerotic lesions, and episodes of  transient unilateral facial nerve palsies, affecting both the 
upper and lower face, with recovery within a month.
Family 4. The index patient (F4-1), the second child of  healthy White parents of  Northern European 
ancestry, is a 6-year-old girl with severe vertebral compression fractures and a history of  6 long-bone frac-
tures. The skull radiograph at 6 years of  age was normal. She has not had neurological symptoms. Bisphos-
phonate treatment resulted in notable improvement in back pain and quality of  life.
Family 5. The index patient (F5-1) is a 44-year-old Dutch female who presented shortly after birth with 
a clavicular fracture and bilateral femoral fractures. She underwent femoral osteotomy at 2.5 years and 
intramedullary rodding at 15 years but continued to have multiple fractures. She had recurrent transient 
facial nerve paralysis, recovering each time within 4–6 weeks, at age 13, 20, and 41 years; unexplained 
transient diplopia at 30 years; and unilateral transient ptosis at 44 years. She experienced progressive hear-
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Figure 1. Characteristics of the 6 families with osteoporosis and a heterozygous SGMS2 mutation. (A) Pedigrees of the 6 families. Squares represent 
males, circles represent females, black symbols represent affected family members, white symbols represent unaffected family members, and slashes 
deceased family members. Individuals with a confirmed mutation are marked with an asterisk, and mutation-negative individuals are marked with N. 
Codes refer to individual data in the text and in Tables 1 and 2. (B) Patient 4-1 with a p.Arg50* mutation has at 6 years severe osteoporosis with spinal 
compression fractures involving all vertebrae. (C) Patient F3-1, with the same p.Arg50* mutation, has at 7 years on spinal magnetic resonance imaging 
multiple compression fractures involving nearly every thoracic and lumbar vertebra and moderate syringomyelia of the upper thoracic spine involving levels 
T3-T8. (D) Patient F3-2 has at 13 years sclerotic lesions in the left frontal bone and the right parietal bone. (E) Patient F5-1 with the Ile62Ser mutation has 
at adult age severe skull hyperostosis with sclerotic and lytic lesions throughout the skull. (F) Patient F6-1 with the p.Met64Arg mutation has at 11 years 
severe spondylometaphyseal dysplasia with poorly mineralized bones, short and wide long bones with metaphyseal widening, abnormal bone texture, and 
bilateral coxa vara.
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ing loss after 25 years of  age. Since adulthood she has suffered from progressive ataxia due to sensory 
neuronopathy. Her son (F5-2) had a clavicular fracture after birth and a femoral fracture at 8 months. Bis-
phosphonate treatment was commenced at 2.6 years because of  a radius fracture, lower limb bowing, and 
platyspondyly and discontinued at age 6 years; no new fractures have occurred thereafter. At 8 years of  age, 
he was diagnosed with transient peripheral facial nerve palsy.
Family 6. The index (F6-1) is an 11-year-old boy of  Hispanic ancestry with severe early-onset osteoporosis, 
with multiple long bone fractures beginning at birth. The radiographic features evolved over time to spondy-
lometaphyseal dysplasia with marked short stature and marked scoliosis. He had normal skull radiographs 
at birth but developed progressive severe cranial sclerosis. Additional findings included sensorineural hearing 
loss, myopia, dilated aortic root, and hypotonia with abnormal myopathic electromyography but normal mus-
cle biopsy. He was also diagnosed by a pediatric neurologist with decreased bulbar function (facial diplegia) at 
5 years, which was no longer present in neurological evaluation at 11 years. He underwent several courses of  
bisphosphonate treatment from infancy to age 4 years and has not had further long-bone fractures.
Identification of SGMS2 mutations
We arrived at the genetic conclusions independently in each family using next-generation sequencing. 
Whole-exome sequencing (WES) was performed for family 1 at Institute for Molecular Medicine Finland 
(FIMM) (Helsinki, Finland), for families 3, 4, and 6 at the University of  Utah, and family 5 at University 
Medical Center Utrecht. Whole-genome sequencing was performed for the index subject in family 2 at the 
Science for Life Laboratory. All genetic findings were confirmed by Sanger sequencing.
We identified heterozygous SGMS2 variants in 13 affected subjects from 6 unrelated families alto-
gether (Figure 1A and Supplemental Figure 1; supplemental material available online with this article; 
https://doi.org/10.1172/jci.insight.126180DS1). In family 1, exome sequencing identified a c.148C>T 
variant, which introduces a premature stop codon in exon 2 (p.Arg50*). The same variant was detected 
in affected individuals in families 2 and 3. In family 4, the same c.148C>T variant was identified de novo. 
In family 5, exome sequencing identified a de novo c.185T>G (p.Ile62Ser) variant in the affected mother; 
her affected son harbored the same missense variant. In family 6, exome sequencing identified a de novo 
Table 2. Clinical findings in the 3 subjects with a heterozygous missense variant in the SGMS2 gene.
F5-1 F5-2 F6-1
Relationship Index Son Index
Pathogenic variant p.Ile62Ser p.Ile62Ser p.Met64Arg
Sex Female Male Male
Age (yr) 43 7 11
Height (SDS) –4.5 –5.0 –7.3
Peripheral fx Multiple 5 Multiple
Spinal fx Platyspondyly Platyspondyly Platyspondyly
BMD Z-score No BP treatment: LS –3.1 (age 43 yr) After BP: LS –0.2, WB –1.8 (age 7 yr) After 2 infusions of BP: LS –4.0,  
WB –3.6 (age 10 yr)
Skeletal dysplasia Scoliosis, femoral bowing with 
osteotomies
Spondylometaphyseal dysplasia, 
scoliosis, femoral bowing (no surgeries)
Spondylometaphyseal dysplasia with 
osteopenia, severe scoliosis (90°), 
occipitocervical instability
Skull findings Wormian bones, diffuse hyperostosis 
of the neurocranium, several frontal 
lucencies, doughnut-lesions
CT at age 9 yr: multiple parasagittal 
parietal doughnut lesions and thickened 
skull base
Calvarial thickening with mixed lytic and 
sclerotic foci throughout the calvarium, 
skull base, and in the visualized upper 
cervical spine
Development N/A Motor delay Mild motor delay
Neurology Three episodes of facial paresis, one 
episode of diplopia, sensory neuropathy, 
ataxia, absent patellar and Achilles 
reflexes, decreased arm reflexes
At 8 yr transient unilateral facial nerve 
palsy
Facial diplegia, decreased bulbar 
function, hypotonia, mild delay in motor 
development
Other Mixed hearing loss, myopia, adult-
onset slow transit constipation with 
dolichocolon, depression
None Unilateral moderate mixed hearing loss; 
CPAP for sleep apnea myopia, dilated 
aortic root, mixed lung disease
BMD, bone mineral density; fx, fracture; BP, bisphosphonate; LS, lumbar spine; fem, femoral neck; WB, whole body; N/A, not available.
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c.191T>G (p.Met64Arg) variant in the index. All these variants were absent in databases (dbSNP, ExAC, 
gnomAD) and were not found in >180 Finnish controls by Sanger sequencing.
Skeletal characteristics in patients with SGMS2 pathogenic variants
The affected subjects shared several skeletal findings, including low-bone mineral density combined with 
increased peripheral and/or spinal fractures, often but not always associated with sclerotic cranial lesions 
(Tables 1 and 2, Figures 1 and 2, and Supplemental Figure 2). The skeletal findings varied in severity: 
the 10 patients with SGMS2 variant p.Arg50* had a milder phenotype, with increased bone fragility but 
without major deformities or height deficit (Table 1; Figure 1, B–D; and Supplemental Figure 2). In 
contrast, the 2 subjects with p.Ile62Ser and 1 subject with p.Met64Arg had multiple spinal and long-bone 
fractures of  neonatal onset, severe short stature, and radiographic evidence of  spondylometaphyseal 
dysplasia (metaphyseal changes associated with marked platyspondyly and scoliosis). Furthermore, the 
degree of  cranial sclerosis was considerably greater in these patients (Table 2; Figure 1, E and F; Figure 
3; and Supplemental Figure 3). Biochemical parameters were mostly normal, but alkaline phosphatase 
and other bone turnover markers tended to be elevated (Supplemental Tables 1 and 2).
To gain further insight into bone tissue characteristics, we reevaluated transiliac bone biopsy samples from 
patient F1-1 and patient F2-1, obtained at age 12 and 15 years at Children’s Hospital, University of Helsinki, 
using identical tetracycline labeling and sample preparation protocols, and a femoral bone biopsy from patient 
F5-1, obtained at age 15 years during a surgery to correct femoral bowing by osteotomy followed by intramedul-
lar rodding. The biopsy was taken at the osteotomy area and far from the growth plate without a preceding tet-
Figure 2. Characteristics of the skull lesions. (A) Skull radiographs of 3 patients with the p.Arg50* mutation showing 
extensive sclerotic lesions in patient 1-2 at adult age. (B) On computerized tomography, the lesions have mixed sclerot-
ic and lytic appearance. Patient F2-1 has only one single sclerotic lesion at the age of 15 years (C) while patient F4-1 has 
normal skull radiograph at 6 years (D).
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racycline labeling. The transiliac biopsies showed variable outcomes (Supplemental Table 3): bone volume was 
normal in patient F1-1 and reduced in patient F2-1. In both patients, trabecular thickness was decreased, and 
cortical bone was reduced in thickness and showed remarkable trabecularization (Figure 4). Patient F2-1 had 
highly increased osteoid volume, thickness, and surface, while these parameters were reduced in patient F1-1. 
Parameters of bone resorption indicated increased osteoclast numbers in both patients (Supplemental Table 3). 
Polarized light microcopy revealed in all 3 samples that bone matrix was predominately formed by haphazard 
arrangement of collagen fibrils (woven bone), while a regular lamellar arrangement of collagen fibrils character-
istic for normal mature bone was sparse (Figure 4 and Supplemental Figure 4). Moreover, numerous parallelly 
oriented birefringent fibers (Sharpey’s fibers) interfusing the cortical bone were seen in patient F1-1 (Figure 4).
In transiliac bone biopsies bone mineralization density distribution (BMDD) for cancellous bone 
showed distinctly reduced mineral content, increased heterogeneity in matrix mineralization, and a highly 
increased portion of  lowly mineralized bone in both patients compared with reference data (Figure 4, 
Supplemental Figure 5, and Supplemental Table 4). The BMDD of  cortical bone showed a peak shift to 
higher mineralization in patient F1-1, while in patient F2-1 the BMDD was shifted toward reduced bone 
matrix mineralization, as in trabecular bone. The increase of  cortical mineralization in patient F1-1, how-
ever, coincided with the appearance of  Sharpey’s fibers interfusing highly mineralized primary bone, indi-
cating that at this cortical site ligaments or tendons were adhering (Figure 4, Supplemental Figure 5, and 
Supplemental Table 4). Details of  the bone tissue at higher magnification further indicated that osteocyte 
lacunae were larger and more irregular in shape than in normal mature lamellar bone (Figure 4). Raman 
microspectroscopic analyses suggested decelerated mineral accumulation kinetics and reduced pyridino-
line, a cross-linking compound of  mature collagen fibers (Supplemental Figure 6).
SGMS2 is prominently expressed in cortical bone
We evaluated mRNA expression of  Sgms2 in a murine tissue panel and found the highest expression 
in cortical bone, followed by vertebrae, kidney, and liver (Figure 5A) Expression levels were very low 
in spleen, muscle, heart, brown fat, and thymus. These results are in line with a bone-critical function 
of  SMS2. In vitro–cultured primary murine osteoblasts, bone marrow macrophages, and osteoclasts all 
expressed Sgms2 at similar levels (Figure 5B).
Figure 3. Skeletal characteristics. Radiographs of patient F5-2 with the p.Ile62Ser mutations at age 1–4 months showing thin ribs (A), abnormally 
short, wide, and poorly mineralized long bones in the arm (B) and leg (C). The proximal humerus and distal femur have abnormal metaphyses with 
pikes (arrows) reminiscent of those seen in hypophosphatasia. At 4 months, the long bones are poorly mineralized and show marked undertubulation 
with metaphyseal widening of the distal femur (D). Skull is osteopenic and does not show wormian bones or sclerotic lesions (E). Pelvis shows under-
mineralization but regular iliac wings and abnormally wide and poorly mineralized proximal femurs (F).
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Effect of SGMS2 pathogenic variants on osteoclast differentiation and function
Because the patients’ imaging studies and transiliac bone biopsies suggested that osteoclast numbers 
might be increased, a finding previously reported in CDL (6), we evaluated osteoclast formation and 
function using peripheral blood monocytes from 2 patients with the p.Arg50* mutation (F1-1 and F2-1). 
The details of  these experiments are presented in the Supplemental Methods. Both patients had normal 
levels and proportions of  peripheral blood monocytes but an increased proportion of  monocytes with 
surface expression of  M-CSF receptor and vitronectin receptor, both of  which are required for normal 
osteoclastogenesis (7–9) (Supplemental Figure 7). When CD14+ monocytes were cultured in the pres-
ence of  M-CSF and RANKL to induce osteoclast differentiation (10), the SGMS2 mutation had no effect 
on osteoclast morphology (Supplemental Figure 8). On plastic, at optimal concentration of  RANKL, no 
obvious differences between patients and controls were seen (Supplemental Figure 9). When monocytes 
were differentiated in the presence of  M-CSF and RANKL on bone discs, the patients’ osteoclasts had 
a similar morphology as the controls and formed resorption pits and actin rings (Supplemental Figure 
8). The resorptive capacity showed no consistent differences from the controls (Supplemental Figure 
10). Increased expression of  M-CSF receptor could indicate that monocytes are more prone to M-CSF–
induced expansion of  a cell lineage, which can give rise to macrophages, osteoclast progenitors, and den-
Figure 4. Bone tissue characteristics. (A) Quantitative backscatter electron imaging (qBEI) of the transiliac bone biopsy samples. Top: There is no clear 
separation between the trabecular and cortical compartment. Pixel gray levels correspond to mineral content (bright to higher and dark to lower). Scale 
bars: 200 μm; 100 μm (zoom). Nonmineralized Sharpey’s fibres are infusing the cortex (solid white arrows, zoomed-in areas), clearly identified by polarized 
light microscopy (see C). Bottom: Bone mineralization density distribution (BMDD) curves for the 2 patients. Ref, reference BMDD for children (66). BMDD 
for cancellous bone showed reduced mineral content, increased heterogeneity in matrix mineralization, and highly increased portion of lowly mineralized 
bone. In cortical bone of patient F1-1, the BMDD showed a peak shift to higher mineralization due to increased proportion of primary bone mineralized to a 
higher extent. In patient F2-1, the cortical bone mineralization was overall reduced. (B) Confocal laser scanning microscopy (CLSM) of fluorescence labeled 
bone. Left: CLSM image of a mineralizing surface shows diffuse appearance of double labeling. Right: Corresponding qBEI image (identical bone area; scale 
bar: 200 μm). Of note, the osteocyte lacunae are enlarged and of abnormal shape. (C-E) Polarized light microscopy of the bone samples. Paired images of 
bright-field (right) and linear polarized (left) light (scale bars: 100 μm). (C) Cortical detail of patient F1-1 (region close to zoomed-in area of A): predominantly 
woven bone infused with Sharpey’s fibres (thin white and black arrows) and bone formation (thick empty black and white arrows) and resorption (thick black 
arrow in C and thick empty white arrows in A). Of note, the new osteoid does not show a lamellar fibril arrangement. (D and E) Examples of bone tissue with 
coexisting woven and lamellar bone matrix. Of note, an osteon (arrows) has woven character in the center though at the peripheral region it is lamellar.
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dritic cells. The increased expression of  integrin suggests that osteoclasts could be more active in bone 
resorption (11, 12), but this could not be confirmed by measuring osteoclast activity in vitro.
Effect of SGMS2 pathogenic variants on blood metabolites
Untargeted metabolomics using direct-infusion high-resolution mass spectrometry in dried bloodspots of  
12 patients did not reveal any hydrophilic small-molecule biomarkers associated with the SGMS2 variants 
(data not shown). Determination of  serum sphingosine-1-phosphate (S1P) concentration by immunoassay 
in 3 affected subjects (F1-1, F1-2, and F2-1) and 4 unaffected controls revealed no difference between the 
groups (affected, 6.70 ± 1.14 [SD] μM; unaffected, 6.67 ± 1.64 μM).
Effect of SGMS2 pathogenic variants on enzyme localization and de novo sphingomyelin 
biosynthesis
The p.Arg50* mutation is predicted to yield a truncated SMS2 protein lacking the entire membrane-span-
ning core domain, which includes the active site (Figure 6). Heterologous expression of  SMS2-Arg50* 
gave rise to a protein that was completely mislocalized in the cytosolic and nuclear compartments of  HeLa 
cells (Supplemental Figure 11) and failed to support sphingomyelin production in yeast (Figure 7A). On 
the other hand, the p.Ile62Ser and p.Met64Arg missense variants did not interfere with SMS2 catalytic 
activity (Figure 7A). However, whereas WT SMS2 predominantly localized at the plasma membrane, both 
SMS2-Ile62Ser and SMS2-Met64Arg accumulated in the endoplasmic reticulum (ER) (Figure 6C). Ile62 
and Met64 are part of  a conserved sequence motif  (I-X-M-P) located 13–14 residues upstream of  the first 
membrane span in both SMS2 and the Golgi-resident isoenzyme SMS1 (Figure 6B). This motif  may repre-
sent an ER export signal, in line with its absence in the ER-resident isoenzyme SMSr.
We next analyzed the consequences of  SGMS2 pathogenic variants on cell proliferation, endogenous 
SMS2 expression levels, and sphingomyelin biosynthetic capacity using fibroblasts derived from patients 
and healthy controls. We did not observe any variant-associated differences in cell proliferation, viability, 
or SMS2 transcript levels (data not shown). None of  the variants had any major effect on cellular SMS2 
protein levels (Figure 7B). SMS2 catalyzes a reaction in which the phosphocholine head group of  phospha-
tidylcholine is cleaved off  and transferred onto ceramide, yielding sphingomyelin and diacylglycerol (13). 
Metabolic labeling of  patient-derived fibroblasts with 14C-choline indicated that the heterozygous p.Arg50* 
variant had no obvious effect on the cellular sphingomyelin biosynthetic capacity (Figure 7D and Supple-
mental Figure 12). However, in contrast to the p.Arg50* nonsense variant, heterozygous p.Ile62Ser and 
p.Met64Arg missense variants caused a marked increase in the rate of  sphingomyelin biosynthesis (Figure 
7, C and D). Moreover, while steady-state levels of  sphingomyelin, phosphatidylcholine, ceramide, and 
diacylglycerol in patient-derived and control fibroblasts were largely comparable, fibroblasts carrying the 
p.Ile62Ser or p.Met64Arg missense variants contained elevated levels of  triacylglycerol (Figure 7E and 
Figure 5. Expression of Sgms2 in tissues and cells. (A) Gene expression of Sgms2 in different tissues from C57BL/6N female 
mice. (B) Gene expression of Sgms2 in in vitro–cultured murine primary calvarial osteoblast, cultured in the absence or 
presence of BMP2, and in cultured murine bone marrow–derived macrophages cultured in M-CSF and osteoclasts cultured in 
M-CSF and RANKL. Data are displayed as fold change versus liver in A, and versus osteoblasts (ctrl) in B ± SEM.
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Supplemental Figure 13). As sphingomyelin biosynthesis is directly coupled to phosphatidylcholine turn-
over and the release of  diacylglycerol, we postulate that an accumulation of  diacylglycerol in the ER of  
p.Ile62Ser and p.Met64Arg fibroblasts is countered by its rapid metabolic conversion into triacylglycerol.
Collectively, our findings suggest that the underlying cause of  osteoporosis and skeletal dysplasia in 
patients with pathogenic variants in SGMS2 is not a reduced cellular capacity to synthesize sphingomyelin 
but rather a perturbation in sphingomyelin metabolism at the plasma membrane.
Discussion
We identified heterozygous pathogenic variants in the SGMS2 gene encoding plasma membrane–resident 
SMS2 in patients with rare forms of  osteoporosis. The clinical presentations ranged from isolated child-
hood-onset osteoporosis to severe generalized bone involvement (spondylometaphyseal dysplasia) with neo-
natal fractures and marked cranial hyperostosis. The milder phenotype was associated with the p.Arg50* 
nonsense variant, identified in 10 individuals in 4 unrelated families, whereas the more severe phenotype 
was associated with closely localized missense variants, p.Ile62Ser and p.Met64Arg. The p.Arg50* muta-
tion resulted in expression of  a catalytically nonfunctional enzyme, whereas the 2 missense variants caused 
retention of  enzymatically active SMS2 in the ER, presumably by disrupting an ER export signal. All 3 
Figure 6. SGMS2 missense variants p.Ile62Ser and 
p.Met64Arg block SMS2 export from the ER. (A) 
Predicted membrane topology of SMS2. Active site 
residues and the first of 6 membrane spans, TM1, are 
marked in red and purple, respectively. The positions 
of 3 residues substituted by osteoporosis-associated 
SGMS2pathogenic variants, i.e., Arg50 (p.Arg50*), 
Ile62 (p.Ile62Ser), and Met64 (p.Met64Arg), are indi-
cated. (B) Sequence alignment of the region immedi-
ately upstream of TM1 in vertebrate SMS family mem-
bers. Note that the human SMS2 residues Ile62 and 
Met64 are conserved between SMS2 and SMS1, but not 
SMSr, across different vertebrate species. Database 
accession numbers for the sequences are human 
SMS2, Q8NHU3; chicken SMS2, F1NLG9; frog SMS2, 
Q28DN3; zebrafish SMS2, B8A5Q0; human SMS1, 
Q86VZ5; chicken SMS1, Q7T3T4; frog SMS1, F6UTK5; 
zebrafish SMS1, A0JMN0; human SMSr, Q96LT4; chick-
en SMSr, F1NI82; frog SMSr, F6SHG1; zebrafish SMSr, 
A4QNV5. (C) HeLa cells cotransfected with Flag-tagged 
SMS2, SMS2I62S, or SMS2M64R and PM marker Lyn-FRB-
mCherry (red) were costained with anti-Flag (green) 
and anti-calnexin antibodies (ER) and visualized by 
fluorescence microscopy. Scale bar: 10 μm.
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pathogenic variants led to decreased bone mineralization in both cortical and trabecular bone. Our results 
demonstrate that SMS2 has bone-regulatory properties and point to a critical role of  plasma membrane 
sphingomyelin metabolism in normal skeletal homeostasis.
Multiple factors contribute to bone strength, including bone mass, bone microarchitecture, and material 
properties related to bone matrix mineralization and arrangement of collagen and collagen fibrils (14, 15). Sever-
al of these characteristics were negatively affected by the SGMS2 pathogenic variants. In particular, we observed 
a reduction in bone matrix mineralization. This seems to be due to alterations in the mineralization process itself  
rather than an abnormally high bone turnover (16, 17). This is in line with our finding that the bone resorptive 
capacity of patient-derived osteoclasts was unaffected. Moreover, bone biopsies showed that the regular lamellar 
bone matrix was severely disturbed (18). The mesh-like appearance of bone matrix and the marked increase in 
osteocyte lacunar density and size are characteristic for primary bone, known to be of low bone strength (19, 20). 
Moreover, microspectroscopy indicated deceleration of mineral accumulation kinetics with tissue maturation 
and low content of pyridinoline, which is needed for proper crosslinking of collagen fibrils. Although no biopsy 
material was obtained from the CDLs, one could speculate that they are caused by remnants of primary bone 
with an elevated degree of mineralization. The measured circulating bone turnover markers showed variable 
results and did not fully correlate with the bone tissue characteristics, which is in line with our previous observa-
tions that these markers reflect bone biopsy findings poorly in both children and adults (21, 22).
Inborn errors of  phospholipid metabolism are emerging as relevant causes for disturbed bone homeosta-
sis (23). In particular, alterations in the choline pathway have been documented in at least 2 skeletal dysplasia 
phenotypes. Pathogenic variants in the phosphatidylserine synthase 1 gene (PTDSS1) cause Lenz-Majewski 
syndrome (MIM #151050), characterized by craniofacial, dental, and limb abnormalities (24, 25). Pathogenic 
Figure 7. Effect of SGMS2 pathogenic variants on SMS2 catalytic activity and sphingomyelin biosynthesis. (A) Top: TLC analysis of reaction prod-
ucts formed when lysates of yeast strains expressing WT or mutant versions of V5-tagged human SMS2 were incubated with C6-NBD-ceramide for 20 
minutes at 37°C. Note that SMS2I62S and SMS2M64R produce similar amounts of NBD-sphingomyelin (NBD-SM) as WT-SMS2, whereas SMS2R50X and the 
active site mutants SMS2D276E and SMS2D276A lack sphingomyelin synthase activity. EV denotes yeast lysate from strain transfected with empty vector. 
Bottom: SMS2 levels in yeast lysates were analyzed by immunoblotting using anti-V5 antibody. (B) Total membranes of control (WT) or patient-de-
rived fibroblasts carrying heterozygous p.Arg50*, p.Ile62Ser, or p.Met64Arg nonsense and missense variants were subjected to immunoblot analysis 
using anti-SMS2 and anti-calnexin antibodies. Immunoblot of total membranes from yeast transfected with empty vector (EV) or SMS2-encoding 
plasmid was stained with anti-SMS2 antibody and served as control. (C) TLC analysis of lipid extracts from control (WT) or patient-derived fibro-
blasts carrying heterozygous p.Ile62Ser or p.Met64Arg missense variants grown for 4 hours in medium supplemented with 14C-choline. Incorporation 
of 14C-choline into phosphatidylcholine (PC) and sphingomyelin (SM) was analyzed by autoradiography (top). Lipids were stained with iodine vapor to 
verify that total lipid content between extracts was comparable (bottom). (D) Quantitation of 14C-choline incorporation into sphingomyelin in control 
or patient-derived fibroblasts treated as in C. Data are mean ± SD; n ≥ 3. (E) Sphingomyelin, phosphatidylcholine, and triacylglycerol (TAG) levels 
in total lipid extracts of control or patient-derived fibroblasts were determined by LC-MS/MS and expressed as mole percent of total phospholipid 
analyzed. Data are mean ± SD; n = 3.
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variants in the PCYT1A gene, encoding CTP-phosphocholine cytidylyltransferase, a key enzyme in the de 
novo phosphatidylcholine biosynthesis, cause spondylometaphyseal dysplasia with cone-rod dystrophy (MIM 
#608940) with normal development (26). Our study expands these findings by providing the first link to our 
knowledge between sphingolipid metabolism and a human bone disease. S1P, which is generated through cer-
amide deacylation followed by phosphorylation by sphingosine kinases, is known to play a fundamental role 
in bone metabolism, specifically in the functional coupling of  osteoblasts and osteoclasts (27, 28). S1P lyase 
is emerging as a potential target for osteoporosis therapy (29). A defect in plasma membrane SMS2 activity 
could alter the local ceramide concentrations and disturb S1P synthesis. However, our analyses showed unal-
tered serum S1P concentrations in affected subjects, suggesting that the pathology is not S1P dependent.
In mice deletion of  the gene encoding sphingomyelin phosphodiesterase 3 (Smpd3) impairs bone and 
cartilage mineralization, leading to severe skeletal deformities (30). Although a cell-autonomous role of  
Smpd3 in bone mineralization has been established (31), it remains unknown how Smpd3 contributes to 
normal skeletal homeostasis. Our present findings underscore a crucial role for sphingomyelin metabolism 
in skeletal mineralization. SMPD3 is a membrane-bound enzyme that cleaves sphingomyelin to generate 
ceramide and phosphocholine on the cell surface. Phosphocholine released by SMPD3 may provide a source 
of  phosphate to promote bone mineralization (32–34). Unlike SMPD3, however, SMS2 catalyzes a reaction 
whereby phosphocholine is cleaved from phosphatidylcholine and subsequently transferred onto ceramide 
to generate sphingomyelin and diacylglycerol. Even though SMS2 can also catalyze the reverse reaction (13), 
the enzyme is unable to release phosphocholine and instead forms a histidine-phosphocholine intermediate 
during the reaction cycle (35). However, by regenerating sphingomyelin from ceramide released by SMPD3, 
SMS2 may serve to replenish the sphingomyelin pool used by SMPD3 to liberate phosphocholine during 
bone mineralization (Figure 8). The abundant expression of  SMS2 in cortical bone implies a high demand 
for SMS2 activity at the plasma membrane to enable this process. All 3 SGMS2 pathogenic variants identi-
fied in this study would diminish the pool of  active enzyme at the plasma membrane by disrupting SMS2 
catalytic activity (p.Arg50*) or ER export (p.Ile62Ser, p.Met64Arg). This may hamper a continuous supply 
of  phosphocholine required for normal bone mineralization, causing osteoporosis.
Immunoblot analysis of patient-derived fibroblasts revealed that the p.Arg50* mutation has no major effect 
on total SMS2 expression, suggesting that expression from the unaffected allele may be increased to compen-
sate for the loss of full-length protein from the affected allele. Whether this scenario also holds for patient-de-
rived bone cells remains to be established. Given that SMS2 is abundantly expressed in cortical bone, further 
upregulation of SMS2 expression from the WT allele to compensate for the p.Arg50* mutation in bone cells 
may no longer be feasible. In addition, robust expression of a 49-residue-long N-terminal SMS2 fragment may 
have a dominant-negative effect on the bone regulatory properties of the full-length protein. As our anti-SMS2 
antibody was raised against the protein’s C-terminus, we have not been able to verify the latter scenario.
A puzzling aspect is that removal of  Sgms2 in mice ameliorates diet-induced obesity and insulin resistance 
but is not known to cause any overt bone defect (36, 37). While a bone phenotype in Sgms2 KO mice may have 
been overlooked, the SGMS2 pathogenic variants described in this study may also have a dominant-negative 
effect on bone formation. As SMS2 is known to form homodimers (38), expression of  the p.Ile62Ser and 
p.Met64Arg missense variants may cause a partial retention of  the WT enzyme in the ER. Bulk production of  
Figure 8. Model on the role of sphingomyelin metabolic enzymes in bone mineralization. Sphingomyelin phosphodi-
esterase 3, SMPD3, cleaves sphingomyelin (SM) in the exoplasmic leaflet of the plasma membrane to generate ceramide 
(Cer) and phosphocholine (P-Chol). P-Chol serves as a substrate for phosphocholine phosphatase PHOSPHO1 to release 
phosphate and promote bone mineralization. Plasma membrane–resident sphingomyelin synthase SMS2 regenerates 
SM from Cer released by SMPD3, using phosphatidylcholine (PC) as head group donor and forms diacylglycerol (DAG) as 
by-product. Coupling of SMPD3 and SMS2 enzymatic activities on the surface of osteoblasts enables a continuous supply 
of phosphocholine required for normal bone mineralization. Release of DAG, a potent signaling lipid, provides a potential 
cue for osteoblasts to fine-tune supply of lipid-derived phosphate.
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sphingomyelin in the ER may be detrimental for the central function of  this organelle in calcium homeostasis, 
stress signaling, and secretion, in particular in bone cells where SMS2 is abundantly expressed. In fact, this 
may explain why the p.Ile62Ser and p.Met64Arg missense variants cause a more severe bone phenotype than 
the p.Arg50* nonsense variant. In addition, SMS2 serves as important crossover between 2 key signaling lip-
ids with opposing biological effects: ceramide and diacylglycerol. Recent work revealed that SMS2-generated 
diacylglycerol at the plasma membrane is critical for the development of  insulin resistance and controlled 
by GPRC5B-mediated SMS2 phosphorylation (39). Diacylglycerol is a key component of  a PKCδ-operated 
pathway that promotes bone formation (40). Consequently, pathogenic variants in SGMS2 may also affect 
normal skeletal homeostasis by perturbing diacylglycerol signaling at the osteoblast plasma membrane.
In addition to the skeletal disease, several subjects had neurological manifestations. The transient nerve 
palsies, most commonly involving the cranial nerve VII and presenting as Bell’s palsy, were more prevalent and 
had earlier onset in patients with missense variants as compared with patients with p.Arg50* mutation, who 
only had cranial nerve palsies at adult age. One patient with p.Ile62Ser was also diagnosed with progressive 
ataxia due to sensory neuronopathy. Recurrent facial nerve palsy has been reported in one patient with CDL 
(41), while several other publications on CDL (6, 42–44) lack information on potential neurological symp-
toms. There are several plausible mechanistic explanations: compression due to cranial sclerosis, as previously 
suggested (5); basilar invagination due to compromised bone strength, as in OI (45), although no evidence for 
that was noted in our patients; and neurotoxicity induced by aberrant sphingomyelin metabolism, similar to 
neuronal damage with incidental cranial nerve palsies in acid sphingomyelinase deficiency (Niemann-Pick 
disease) (46). In the patients with missense variants, accumulation of SMS2 and production of sphingomyelin 
in the ER could also lead to a lipid-mediated cellular stress response with adverse effects on neuronal function 
(47). The transient nature of the cranial nerve palsies remains unexplained. Further, it remains unclear whether 
the several other symptoms in our patients (Tables 1 and 2) are manifestations of SGMS2 pathogenic variants.
In summary, our findings indicate that SGMS2 pathogenic variants impair bone material properties, result-
ing in disturbances in mechanical competence; development and growth of the skeleton; and underlie a spec-
trum of skeletal conditions, ranging from early-onset osteoporosis to osteoporosis with skeletal dysplasia. These 
findings suggest a critical role for plasma membrane–bound sphingomyelin metabolism in skeletal homeostasis 
and in bone mineralization. Patients’ skeletal features, bone tissue characteristics, and the observed gene expres-
sion pattern, involving both osteoblasts and osteoclasts and being highest in the cortical bone, indicate a need to 
further explore the role of SGMS2 in osteoblast and osteocyte function. Moreover, recent studies (48, 49) have 
demonstrated expression of SGMS2 in primary chondrocytes isolated from patients with osteoarthritis, prompt-
ing the study of SGMS2 function also in this cell type. Our study underscores a wide range of presentations 
associated with SGMS2 pathogenic variants and shows correlation with genotype. Bisphosphonate treatment 
seemed to have a beneficial effect, but long-term effects remain unknown. Further insights into the underlying 
molecular and biochemical mechanism may identify novel pharmacologic targets to improve bone strength.
Methods
Clinical studies
All study subjects were assessed as part of  ongoing studies at the Helsinki University Hospital, the University 
of  Utah, and the University Medical Center Utrecht. Patient data were collected by interview and from hospi-
tal records for fractures and other skeletal and nonskeletal morbidities, including neurological symptoms and 
evaluations. All patients were clinically examined.
Genetic analyses
WES. Genomic DNA was processed according to an Agilent protocol using the SureSelect Human All Exon v4 
or v5 kit (Agilent Technologies Inc.) and sequencing with the Illumina HiSeq 2000 or 2500 (Illumina Inc.). Bio-
logical parentage was confirmed by short tandem repeat analysis. The reads were aligned to the hg19 reference 
genome, using the variant calling pipeline of the FIMM (50) or using the Genome Analysis Toolkit (GATK ver-
sion 1.6, Broad Institute). The procedure yielded ×49 mean coverage of target bases. In family 1, reannotation 
was made with Annovar (51) and filtering with Excel and VarAFT 2.06 (http://varaft.eu). A comparison was 
made in family 1 between 2 affected subjects (the index and grandmother) and the healthy sibling to detect het-
erozygous variants shared by the 2 affected individuals but not present in the healthy sibling. Filtering of exome 
variants was done for rarity (variant frequency = 0.001 or less in public databases ESP6500, 1000 Genomes, 
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ExAC, Kaviar, Haplotype Reference Consortium, SISu) and quality (WES) data with less than 15 reads per 
nucleotide. Seven variants were retained after this filtering procedure; these variants were Sanger sequenced in all 
family members for whom a DNA sample was available. Three variants were retained after Sanger sequencing: 
an Arg-to-stop gain change (c.148C>T/p.R50X) in the SGMS2 gene coding for a sphingomyelin synthase 2, an 
Ile-to-Val change (c.A499G/p.I167V) in the ALPK1 gene coding for alpha kinase 1, and an Asn-to-Val change 
(c.A335G/p.N112S) in the gene ERC1 gene coding for ELKS/RAB6-interacting/CAST family member 1. After 
filtering variants for predicted deleteriousness (combined annotation dependent depletion [CADD] score = 25 
or more), only the Arg-to-stop gain change (c.148C>T/p.R50X) in the SGMS2 remained.
In families 3, 4, and 6 variants occurring in the known OMIM genes that may be associated with the pheno-
type and rare de novo and/or rare compound heterozygous variants occurring in genes of unknown clinical rel-
evance were investigated. Common variants with a population frequency of greater than 0.001 were filtered out. 
The following population variant databases were used to aid variant filtering and interpretation: dbSNP 151, 
1000 Genomes, gnomAD, and Mutation Database (HGMD) Professional 2017.4 (QIAGEN Bioinformatics).
In family 5, after referral for routine diagnostic exome sequencing, exomes of the affected patient (F5-1) 
and her healthy parents were enriched using the Agilent SureSelect XT Human All Exon kit V6 and sequenced 
in rapid 2 × 100 bp run mode on the HiSeq2500 sequencing system (Illumina Inc.). Reads were aligned to 
reference genome (hg19) using BWA-MEM algorithm (v.0.7.5a), and variants were called using the GATK 
haplotype caller (v3.4.46). Detected variants were annotated, filtered and prioritized using the Bench NGS Lab 
platform (Agilent-Cartagenia). Analysis is based upon a tiered analysis approach. The first tier that filters for de 
novo variants resulted in the detection of the de novo SGMS2 variant. The last tier, which filters for recessive 
variants, did not result in additional candidates. The same heterozygous SGMS2 variant was subsequently iden-
tified in the patient’s affected son (F5-2).
Whole-genome sequencing. For patient F2-1 in family 2, we performed whole-genome sequencing on 
genomic DNA on the Illumina HiSeqX (Illumina Inc.) at the Science for Life Laboratory (NGI facility), 
Stockholm, Sweden. Parental samples were unavailable. Data alignment was performed with the BWA-
MEM algorithm (0.7.12) to reference genome (hg19). GATK Best Practices recommendations (52–54) 
were followed to mark duplicates, recalibrate for base quality scores, realign indels, and call for variants 
using variant quality score recalibration (GATK, suite 3.3 and 3.6). Variants were annotated with the Vari-
ant Effect Predictor (version 86) and loaded as a database into GEMINI (0.19.0). Calls for known OI genes 
were then made with SAMtools (0.1.19) and BEDTools (2.23.0) to exclude pathogenic variants. Calls for 
variants in other new genes, including SGMS2, in which a mutation had previously been identified in family 
1, were made. The computations were performed on resources provided by SNIC through Uppsala Multi-
disciplinary Center for Advanced Computational Science under project b2014258 (55).
Sanger sequencing. We confirmed all detected SGMS2 (NM_001136258) mutations, c.148C>T 
(p.R50X) (families 1–4), c.185T>G (p.I62S) (family 5), and c.191T>G (p.M64R) (family 6), with Sanger 
sequencing using standard protocols. In addition, we Sanger sequenced the SGMS2 gene in 183 samples 
from healthy Finnish controls to exclude the presence of  these variants. Sequencing was performed with 
an ABI 3730 DNA Analyzer (Applied Biosystems), and chromatograms were analyzed using Sequencher 
v5.0 software. Primer sequences and detailed PCR protocols are given in the Supplemental Methods.
Imaging studies
We used radiography and dual-energy X-ray absorptiometry to characterize skeletal features. Radiological 
evaluations, including skeletal radiographs and magnetic resonance imaging and computed tomography 
evaluations of  the brain and spine, were performed as part of  the patients’ clinical care. Bone mineral den-
sity was measured by dual-energy X-ray absorptiometry and converted to Z-scores based on equipment-spe-
cific normative data adjusted for age and sex.
Bone biopsy studies
We analyzed 2 transiliac bone biopsies, obtained from patient F1-1 and patient F2-1, as part of  the 
diagnostic assessment of  osteoporosis at age 12 and 15 years, respectively. The 2 transiliac bone biop-
sies were analyzed using histomorphometry, confocal laser scanning microscopy, polarized light 
microscopy, quantitative backscatter electron microscopy (qBEI), and Raman microspectroscopy to 
evaluate bone tissue characteristics. In addition, surgical bone biopsies from the femur were obtained 
from patient F5-1 at age 15 and 16 years; the bone samples were decalcified and embedded in paraffin. 
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Sections were stained with H&E stain and examined by light microcopy for bone histology. All bone 
biopsies were analyzed simultaneously at the same center and with the same equipment.
Both transiliac bone biopsies were taken at Children’s Hospital, University of  Helsinki, with a standard 
7.5-mm trephine needle from anterior iliac crest (Rochester Bone Biopsy, Medical Innovations International). 
For tetracycline labeling, an identical protocol was used for each patient: 500 mg oral tetracycline was given 3 
times a day in a 2:10:2-day sequence, as previously described (21). Patients also refrained from dairy products, 
calcium supplements, or antacids during the labeling. The transiliac bone biopsy samples were immediately 
fixed and stored in 70% ethanol and subsequently embedded in polymethylmethacrylate using standard pro-
cedures (21). Longitudinal sections of  the bone sample cylinder were obtained. Three-μm-thick sections were 
obtained for bone histomorphometry. The surface of  the residual sample block was flattened by grinding and 
polishing (Logitech PM5) so as to facilitate confocal laser scanning microscopy and qBEI.
The thin bone sections were stained with Goldner′s trichrome method (mineralized matrix green, 
unmineralized matrix/osteoid red). Using a light microscope (Axiophot, equipped with a digital camera, 
AxioCam HRc, Zeiss), structural parameters, as well as parameters of  static bone formation and resorption 
were assessed. A confocal laser scanning microscope (Leica TCS_SP5, Leica Microsystems) was used to 
analyze parameters of  dynamic bone formation from the sectioned bone area at the sample block surface. 
The histomorphometric outcomes were compared with age-appropriate reference values (56).
Bone matrix mineralization was characterized by measurement of  the BMDD using qBEI (57). This 
was performed with a scanning electron microscope equipped with a 4-quadrant semiconductor backscat-
ter electron detector (Zeiss Supra 40) after carbon coating of  the sample surface. The entire cross-sectioned 
bone sample area was imaged with a spatial resolution of  3.6 μm/pixel. The gray levels, reflecting the 
mineral/calcium content, were calibrated by the material contrast of  pure carbon and aluminum; thus, the 
resulting gray level histograms could be transformed into calcium weight percentage (wt% Ca) histograms 
as described previously (58). Five BMDD parameters were derived to characterize the BMDD (Supplemen-
tal Figure 5). The bone mineral density distribution BMDD outcomes of  cancellous and cortical bone were 
compared with a young reference database (59).
The details of  Raman microspectroscopy are presented in the Supplemental Methods.
Gene expression studies
Gene expression in murine tissues, including cortical bone, and in in vitro–cultured primary murine calvarial 
osteoblasts, bone marrow–derived macrophages cultured in M-CSF, and osteoclasts differentiated from bone 
marrow macrophages in the presence of  M-CSF and RANKL for three days was analyzed by real-time quan-
titative PCR. Details are given in the Supplemental Methods.
Evaluation of osteoclast function
To obtain information on osteoclast function, we differentiated patients’ peripheral blood monocytes to osteo-
clasts and determined their characteristics and activity. In vitro osteoclast differentiation was done on plastic 
and bone. The details of  these experiments are presented in the Supplemental Methods. Osteoclast bone 
resorption was evaluated by measuring the release of  collagen type I fragments (CTX-I) in culture media 
using a commercial ELISA (IDS Immunodiagnostics Systems, catalog AC-07F1). Number of  osteoclasts was 
counted in microscope or evaluated by measuring TRAP5b in culture media using a commercial ELISA (IDS 
Immunodiagnostics Systems, catalog SB-TR201A).
Metabolomics and measurement of S1P
To investigate whether there are differences in blood metabolites relevant to bone homeostasis between the 
affected subjects and healthy controls, we investigated untargeted metabolomics using direct-infusion high-res-
olution mass spectrometry (Thermo Scientific) of  dried bloodspots (Supplemental Methods). S1P concentra-
tion was measured with a Sphingosine 1 phosphate Elisa kit (Echelon Biosciences Inc.) from serum samples 
obtained from 3 affected and 4 unaffected subjects in family 1, according to the manufacturer’s instructions.
Fibroblast cultures
The skin biopsy samples were put in sterile culture DMEM medium (Lonza, catalog BE12-614F), 20% 
FBS (Biowest, catalog S181B-500), 50 IU/ml penicillin, and 50 μg/ml streptomycin (Gibco). The skin 
biopsies were cut into small fragments in PBS on a Petri dish and transferred to Falcon tubes containing 
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3 ml PBS (without Mg and Ca) and 1000 U/ml Collagenase Type II: Clostridium histolyticum (Gibco). 
The tubes were incubated at +37°C for 2 hours. Collagenase inactivation was performed by addition of  3 
ml ice-cold medium. The tubes were mixed by vortexing, and tissue lysates were centrifuged for 10 min-
utes, 150 g at +4 °C. The supernatants were removed, the cell pellets were resuspended in 900 μl DMEM 
and transferred to T-25 flasks (Corning Life Sciences). 4 ml of  DMEM was added to each flask, and they 
were incubated in a 5% CO2 humidified incubator at 37°C for 1–2 weeks.
Characterization of patient-derived and control skin fibroblasts
We analyzed cell proliferation, viability, SGMS2 gene expression, steady-state sphingolipid content (cer-
amides, phosphatidylcholines, sphingomyelins), and the capacity of  cells to synthesize sphingomyelin de 
novo in patient-derived and control skin fibroblasts.
To compare cell proliferation in cases versus controls, the same number of  cells (5 × 103) was cultured 
in a 96-well plate and the cells were counted at 30 hours or 1.5 × 105 cells were cultured in the 6-well plates 
(3 wells for cases and 3 for controls) and the cells were counted at 24, 48, and 72 hours. Cell viability was 
measured at 30 hours with CellTiter-Glo 2.0 Assay (Promega).
RNA was isolated from patient-derived and control fibroblasts using the RNeasy kit (Qiagen), cDNA 
was synthesized with QuantiTect Reverse Transcription Kit (Qiagen), and gene expression analysis per-
formed using SGMS2 TaqMan Gene Expression assay (Hs00380453_m1) and for reference genes, ACTB 
and TBP TaqMan Gene Expression assays Hs99999903_m1 and Hs00427620_m1 (Applied Biosystems). 
qPCR reactions were run in CFX96 Real-Time systems (Bio-Rad). The data were normalized with ampli-
fication of  ACTB and TBP genes. Threshold cycle values were determined using CFX Manager Software 
(Bio-Rad). Relative expression was calculated with the 2ΔΔCt method (60, 61).
Lipid composition of fibroblasts
To analyze the steady-state lipid composition of  the fibroblasts, nearly confluent cells were washed twice with 
PBS and then incubated in DMEM containing 10% delipidated FCS for 72 hours in a cell incubator. After 
washing twice with PBS, cells were scraped from the dishes and the lipids were extracted (62). The extract was 
divided in two parts, one (30%) of  which was used to analyze glycerophospholipids, while the other (70%) 
was subjected to alkaline hydrolysis to eliminate phosphatidylcholine, which would hamper quantification 
of  sphingomyelin. The glycerophospholipid fraction was subjected to methylation, and the methylated glyc-
erophospholipids were analyzed by liquid chromatography tandem–mass spectrometry (LC-MS/MS) using 
neutral loss scanning for detection (63). The instrument consisted of  a Waters Acquity H-class UPLC and a 
Micro Premier triple quadrupole mass spectrometer (Waters Corporation). The column (Acquity BEH C4, 1 
× 100 mm) was eluted with a gradient of  75% solvent A (ACN/water/5 mM NH4-formate) to 100 % solvent 
B (ACN/MeOH/5 mM NH4-formate) over 10 minutes. The sphingolipid fraction was likewise analyzed by 
LC-MS/MS, and sphingomyelin was detected by scanning for precursors of  m/z 184, while other sphingolip-
ids were detected by scanning for the precursors of  m/z 264. The mass spectra were analyzed with the LIMSA 
software (64). Diacylglycerol and triacylglycerol were detected using multiple reaction monitoring and ana-
lyzed using the QuanLynx software (Waters Corporation). Quantification was based on the following internal 
standards: PC-28:2, PC-40:2, SM-15:0, SM-25:0, Cer-15:0, Cer-25:0, and DAG-40:2.
Heterologous expression of SMS2 mutant proteins in HeLa cells
A cDNA insert encoding human SMS2 with a N-terminal FLAG tag (DYKDDDDK) was created by 
PCR and inserted into NotI and XbaI restriction sites of  mammalian expression vector pcDNA3.1 (+). 
A yeast pYES2.1 expression construct carrying human SMS2 with a C-terminal V5 and polyHis-tag was 
described in Huitema et al. (13). Disease-related mutations in SMS2 were introduced using site-directed 
mutagenesis and verified by DNA sequencing. HeLa cells were cotransfected with pcDNA3.1-SMS2 
constructs and the plasma membrane marker lyn-FRB-mCherry using Effectene (Qiagen). Cells were 
fixed 24 hours after transfection, immunostained with anti-FLAG and anti-calnexin antibodies, and then 
processed for fluorescence imaging as described previously (65).
Catalytic activity of SMS2 mutant proteins
Yeast strain IAY11 (MATa, ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-52 ade3-Δ853) was transformed with 
pYES2.1/SMS2-V5-His expression constructs and then grown in synthetic medium containing 2% (w/v) galac-
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tose to early mid-logarithmic phase. Cells were collected by centrifugation and washed in ice-cold buffer R (15 
mM KCl, 5 mM NaCl, 20 mM HEPES/KOH, pH 7.2). The wet cell pellet (2 g) was resuspended in a final 
volume of 5 ml buffer R containing protease inhibitors (1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml pepsta-
tin, 5 μg/ml antipain, 1 mM benzamidine, and 1 mM PMSF). Cells were lysed by vigorous vortexing with 3 g 
glass beads at 4°C with intermittent cooling on ice. A postnuclear supernatant was prepared by centrifugation 
at 700 g for 10 minutes at 4°C. After addition of 0.11 volume of glycerol, lysates were aliquoted, snap frozen in 
liquid nitrogen, and stored at –80°C. Lysates from various SMS2-V5–expressing yeast strains were normalized 
for SMS2-V5 levels and protein content by adding appropriate amounts of control lysate and then assayed for 
SMS activity with 25 μM C6-NBD-ceramide in a reaction volume of 100 μl. After 20 minutes at 37°C with 
constant shaking, reactions were stopped by addition of 3.75 volume CHCl3/MeOH (1:2 v/v) and subjected to 
total lipid extraction in protein LoBind tubes (Eppendorff) starting from a reference volume (1 volume) of 100 
μl (sample) in 3.75 volume (375 μl) CHCl3/MeOH (1:2 v/v). After centrifugation at 21,000 g for 10 minutes at 
4°C, the supernatant was transferred to a fresh tube containing 1 volume CHCl3 and 1.25 volume 0.45% NaCl in 
H2O. This 2-phase system was vortexed vigorously for 5 minutes and then centrifuged for 5 minutes at 21,000 g 
and 4°C to complete phase separation. The lower phase was carefully collected with a 1000 μl Hamilton syringe 
and transferred to a fresh tube containing 3.5 volumes of a 1:1 mixture of MeOH/0.45% NaCl in H2O and then 
vortexed and centrifuged as above. Finally, the lower phase was transferred to a fresh tube and dried in a Christ 
RVC 100-2-18 concentrator coupled to a Vacuubrand MZ 2C (9 mbar) diaphragm vacuum pump. The dried 
lipid film was dissolved in CHCl3/methanol (2:1), spotted at 120 nl/s on NANO-ADAMANT HP-TLC plates 
(Macherey-Nagel) using a CAMAG Linomat 5 TLC sampler, and then developed in a CAMAG ADC2 cham-
ber with CHCl3/MeOH/25%NH3(aq) (50:25:6, v/v/v) as an eluent. NBD-fluorescence was detected using the 
Cy2 settings (470/535 Ex/Em) of a Typhoon FLA 9500 Biomolecular Imager (GE Healthcare).
Statistics
Standard statistical methods were used for data analysis, as appropriate. Descriptive statistics are presented 
as mean ± SD. Results were considered significant at the 95% significance level (P < 0.05). In untargeted 
metabolomics, Z-scores were calculated based on average intensities and SD of the metabolites in controls, 
measured in the same technical runs. Student’s 2-tailed t test was used to compare Z-scores in affected patients 
versus unaffected family members. P values were adjusted using Bonferroni correction to control for false-pos-
itive results due to multiple testing.
Study approval
All parts of the study were approved by institutional ethics committees (Helsinki University Hospital, Univer-
sity of Utah Institutional Review Board, and the Medical Ethical Committee of the University Medical Centre 
Utrecht), and informed consent was obtained from study participants and/or their legal guardians prior to the 
study. Subjects in families F-1 and F-2 were assessed as part of an ongoing research program at Helsinki Uni-
versity Hospital (HUS 1088/2016). In families F-3, F-4, and F-6, written consent was obtained for all evaluated 
family members for participation in the research project, including documentation of phenotypic data and the 
WES, through the process established for the Undiagnosed Disease Program and the University Phenotype 
Core and approved by the University of Utah Institutional Review Board. In family, F-5 routine diagnostic 
exome sequencing was performed with written consent of the patients and their parents. The consent for diag-
nostic WES was approved by the Medical Ethical Committee of the University Medical Centre Utrecht. Later, 
written consent was obtained for publication of medical history and outcome of WES analysis.
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